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New  vaccines  are  required  to meet  the  public  health  challenges  of  the  next  generation  and  many  unmet
global  health  needs  can  be  addressed  by  developing  countries  vaccine  manufacturers  such as  lower-cost
vaccines  based  on  single-dose,  thermostable  formulations,  efﬁcacious  in  children  with  compromised
gastrointestinal  tracts.  GMP  compliance  is  also  a challenge,  as  sometimes  innovation  and  clinical  devel-
opment  focus  is not  accompanied  by command  of  scale-up  and  quality  assurance  for large  volume
manufacturing  and  supply.  Identifying  and  addressing  such  challenges,  beyond  cost  and  cold-chain  space,
including  safety  considerations  and  health  worker  behavior,  regulatory  alliances  and  harmonization  to
foster  access  to vaccines,  will help  countries  to  ensure  sustainable  immunization.  There  needs  to be
continuous  and  close  management  of  the  global  vaccine  supply  both  at national  and international  lev-
els,  requiring  careful  risk  management,  coordination  and  cooperation  with  manufacturers.  Successful
partnership  models  based  on sharing  a  common  goal, mutual  respect  and  good  communication  were
discussed  among  stakeholders.. Novel Vaccine Initiatives
An update of Intravacc’s Sabin IPV technology Transfer Initia-
ive to developing countries vaccine manufacturers as a Private
ublic Partnership directly under the Ministry of Health in The
etherlands was provided by A. Hamidi. The Sabin-IPV project
ncludes four main activities: (1) Seed lot production and char-
cterization; (2) preclinical-clinical lot production, phase I/IIa;
3) technology-transfer bilateral agreements with DCVMs; and
4) process ﬁne-tuning and dose optimization. Enough quanti-
ies of master and working seed lots are available. An optimized
rocess has been established and a phase I/IIa, double-blind,
ose-escalation trial (adults and infants) has been successfully
ompleted, demonstrating that Sabin-IPV is safe and immunogenic.
ix different adjuvant formulations with sIPV were tested to study
he feasibility of increasing sIPV potency in rats and thus dose
paring effect, adjuvants used included: aluminum hydroxide, two
qualene-in-water emulsions, two lipopolysaccharide (LPS) deriva-
ives, and Venezuelan equine encephalitis (VEE) replicon particles
GVI3000). It was  established that using Al(OH)3 dose-reduction
as type dependent. Six partner manufacturers from emerging
ountries have been selected for technology transfer. Further points
o consider for product registration include: assays standardiza-
ion; availability of international reference reagents and standards;
 Important  note: This report summarizes the views of an international group of
xperts as presented at a scientiﬁc conference in a given time point and context, and
oes not necessarily represent the decisions or the stated policy of any institution
r  corporation.
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.076
264-410X/ Open access under CC BY-NC-ND license.the design of clinical trials, including protection against wild and/or
Sabin strains and containment strategies.
A. Nanni (AERAS) highlighted the extent of the tuberculosis (TB)
epidemic in the 21st century, with US$8 billion spent annually on
TB-treatment and care in low and middle income countries (MICs).
Multi-Drug Resistant (MDR) TB has been diagnosed in 77 countries.
It is estimated that MDR-TB prevalence will increase by 150% by
2036, without further interventions. There are at least 13 TB vac-
cine candidates in the global clinical development pipeline, based
on different approaches including viral vectors, protein/adjuvant,
rBCG, attenuated M.  Tb and mycobacterial (whole cell or extract).
Clinical trials of these vaccines are also being used as opportuni-
ties to analyze correlates of risk of disease and/or protection. TB
primarily strikes working-age adults and costs the global econ-
omy an estimated US$1 billion daily, particularly in the emerging
economies. For example, for China it is estimated to reach up to
US$1182 billion from 2006 to 2015, and annual cost of TB to the
South African mining sector is over US$880 million. Data generated
by mathematical modeling, estimated that 30–50 million TB cases
can be potentially averted by vaccines in adolescents and adults
by 2050. An additional 7–10 million TB cases could be averted in
infants by 2050, assuming a 2 dose routine vaccination for adoles-
cents/adults at 10 years and mass campaigns in over 11 year olds
every 10 years, and a 1 dose routine vaccination of newborns. It
was estimated that a minimum of 3 suppliers would be required to
meet potential demand within 10 years (Fig. 1), after vaccine intro-
duction (about 250–300 million doses). Within the ﬁrst 10 years,
high income countries and China may  dominate the market returns,
estimated to be potentially $13.6 billion dollars, while in the
same period MICs and China may  dominate the vaccine demand,
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Fig. 1. Early estimates (number of doses) of potential manufacturing needs to satisfy global demand for future TB vaccines, from 2030 to 2015. Two distinct age groups have
been  considered: Infants (depicted by black bars) and adolescents/adults (depicted by gray bars). The dashed line represents the estimated demand of two large countries,
China and India, as compared to total estimated demand (bars). Estimated number of needed vaccine manufacturers/suppliers over time is indicated at the right scale depicted
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uct and WHO  prequaliﬁcation. The JE vaccine has been registered
in 11 countries outside of China with more than 200 million dosesy  a solid line. Courtesy of A. Nanni.
stimated at about 1.6 billion doses. So far US$600 million has been
pent in efforts to develop TB vaccine candidates.
Efforts to develop a live attenuated (LA) tetravalent dengue
accine in partnership with the National Institutes of Allergy and
nfectious Diseases – NIH and the Butantan Institute were reported
y A. Precioso. Dengue incidence has increased 30-fold over the
ast 50 years with up to 100 million infections annually in over
00 endemic countries, in tropical and sub-tropical areas. The LA
accine approach stimulates both cellular and humoral immu-
ity, inducing a strong memory response and durable immune
esponse. LA vaccines for other related ﬂaviviruses such as yel-
ow fever and Japanese encephalitis virus have been successfully
eveloped and LA vaccines can be very economical to produce,
elping to secure vaccine access. Ideally, the vaccine must con-
er protective immunity against all four dengue virus serotypes.
egarding safety, the attenuated virus must not be transmissi-
le via mosquitoes and must show genetic and potency stability.
ix monovalent candidates, developed and tested in pre-clinical
nd initial clinical studies in the USA, demonstrated that each of
onovalent vaccine candidates was attenuated and immunogenic
n mice and Rhesus macaques. The monovalent candidate vac-
ines, evaluated in over 750 volunteers in US, were found to be
afe and immunogenic when administered as a single subcuta-
eous dose of 103 PFU/mL. Subjects did not develop a dengue-like
llness and local reactogenicity was minimal. Studies in ﬂavivirus-
aïve adults (US) demonstrated that the tetravalent mixtures are
afe and viremia remained very low. Immunogenicity measured
fter 90 days demonstrated multivalent seroconversion rate of 74%.
hase II, stepwise, randomized, double-blind and controlled clinical
rial to evaluate the safety and immunogenicity of the lyophilizedformulation of the vaccine made at Butantan started in Brazil in
October 2013.
L.  Yang provided an overview of a successful partnership
between CNBG and PATH2 for the development and global supply of
a live attenuated Japanese encephalitis (JE) vaccine at the Chengdu
Institute for Biological Products (CDIBP) in China. CDIBP has one of
the largest development and manufacture capabilities of biologi-
cal products within CNBG with an annual production capacity for
more than 100 million doses and over 950 staff. The JE project’s
strategy at CDIBP, focused on improving the GMP  level and achiev-
ing WHO  prequaliﬁcation. Critical success factors included the use
of software tools, the organization of the project team, the team-
work spirit and deﬁning the framework or rules for the project
monitoring, measurement and improvement. Key milestones were
deﬁned in 2004 with an assessment by PATH, site inspection by
WHO in May  2013 and prequaliﬁcation in October 2013. CDIBP
invested in 10 state-of-the-art buildings to support the project and
over 200,000 person/hours have been invested in continuous per-
sonnel training. The overall documentation framework consisted
of 4 levels: First: Policies and Quality Manual; Second: Guidelines
and Speciﬁcations; Third: SOPs; Fourth: records and forms. A total
of 12 clinical trials were performed between 1997 and 2012 in
South Korea, Nepal, Philippines, Thailand, India, Sri Lanka, North
Korea, Bangladesh and China, to support registration of the prod-supplied to date. Key areas of learning include: (1) staff needed to
2 China National Biotec Group-Programme for Appropriate Technology in Health.
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e stimulated and inspired; (2) commitment from political lead-
rs was very important; (3) good and clear internal and external
ommunication was critical. Allocation of limited resources to com-
lete the project within the planned timeframe was  an ongoing
hallenge.
N. Imbault, from the European Vaccine Initiative, presented the
frican clinical trials networks, funded by different parties includ-
ng European and Developing Countries Trial Partnership (EDCTP),
uropean Commission (EC), Malaria Vaccine Initiative, PATH, and
eningitis Vaccine Project (MVP). Capacity building activities of
DCTP and upgrades of infrastructure started in 2003, by investing
n long, medium and short term training activities. First round of
linical trials focused on HIV, TB and malaria. Second round will
nclude other neglected diseases such as leishmaniasis, schistoso-
iasis, trachoma. The ﬁrst Network of Excellence (NoE) was the
entral African Network on TB HIV/AIDS and malaria (CANTAM –
ww.cantam.org). The second NoE, the East Africa Consortium for
linical Research (EACCR – www.eaccr.org). The West Africa NoE
or TB, AIDS and Malaria (WANETAM – www.wanetam.org). The
ourth  NoE, located in southern Africa, the Trials of Excellence for
outhern Africa (TESA – www.tesafrica.org). Signiﬁcant investment
as  been made by EDCTP in capacity building in ethics to enable
nstitutional Review Boards and Health Research Ethics Commit-
ees to be functional and independent. EDCTP has also funded the
frican Vaccines and Regulators’ Forum (AVAREF), coordinated by
HO, as a platform for joint review and GCP inspection of Clinical
rials in Africa. EDCTP has established a site ranking process based
n 10 factors ranging from laboratories to sample repository to
nance and administration to ethics. To date 30 projects have been
unded, for microbicides, HIV vaccine candidates, TB treatments,
B vaccine candidates, malaria treatment and malaria vaccine can-
idates. One example of network project is the Malaria Vectored
accine Consortium (MVVC), established in 2010 to develop a
alaria vaccine candidate: a fully GCP compliant site with capacity
n biochemistry, hematology, parasitology and immunology, man-
gement of samples and storage of investigational products such as
accines. The MVP  is another example of a project with study sites
n India, Mali, The Gambia, Ghana and Senegal.
. Partnerships for vaccines’ innovation and access
C.  Loucq gave an overview about the International Vaccine
nstitute (IVI) Technology Transfer activities in Asia. IVI is an Inter-
ational organization working in 35 countries with headquarters
n Korea, funded by the Korean Government, Gates Foundation,
wedish government and also from Korean corporations that
nance some of the projects in Ethiopia and Malawi. IVI works from
Bench to Field” on research, process development, assay develop-
ent, and also on Translational research, focusing on interaction
f vaccines. IVI is focused on enteric diseases, technology transfer
nd related training.
Notably,  IVI worked in cross collaboration with VABIOTEC and
hanta Biotech for the cholera vaccine Shanchol prequaliﬁcation in
011. The vaccine was initially discovered at Vabiotech, licensed
nd then adjusted to WHO  requirements for the prequaliﬁcation.
holera burden is likely to exceed 1 million cases annually with
20,000 deaths annually. To increase capacity and access IVI col-
aborates for technology transfer to Eubiologics in Korea. A clinical
rial was conducted on 65,000 subjects and the vaccine provided
bout 65% protection for at least 3 years and shown to be safe
mong children aged 1–4.9 years. Larger clinical trials for licensure
nd WHO  prequaliﬁcation are planned. This vaccine is primarily
imed for a stock pile in preparing for an eventual epidemic. A
econd project is to make available a high quality, safe and efﬁca-
ious vaccine for Typhoid fever for the population at most risk from32 (2014) 6330–6335
the  infection. As Vi- polysaccharide shows low efﬁcacy levels IVI
aims to develop a conjugated vaccine for typhoid, by optimizing Vi
fermentation, developing novel puriﬁcation process, and improv-
ing the quality of the conjugated vaccine. The selected carrier
protein was Diphtheria Toxoid. The technology is being transferred
to Shanta and SK Chemicals (Korea), as well to Biofarma (Indonesia).
IVI has moved from 5 to 10 L fermentation batches and at the
moment clinical lots are ready for Phase II and III studies in India.
Conditions for technology transfer include that manufacturers
operate in compliance with WHO  cGMP, willing to achieve WHO-
prequaliﬁcation, capacity to scale up, and commitment to supply
public markets. Challenges IVI faces are the changing priorities of
manufacturers (due to mergers and acquisitions) delaying product
development.
K. Ella reviewed challenges of adjuvanted vaccines that today
include two approaches: delivery systems and immunomodulat-
tors. For instance European countries have approved innumerous
adjuvanted vaccines so far, while the US FDA has approved only
two. Bharat Biotech has partnerships for developing adjuvanted
systems, including 23 innovative analogues so far tested in vitro
for safety and toxicity. It is considering setting up a common plat-
form to access intellectual property of adjuvants for use in products
for public health beneﬁt.
PATH’s  innovative approach to developing rotavirus vaccines
in China and product development collaborations with develop-
ing countries manufacturers, supported by Bill & Melinda Gates
Foundation (BMGF),was presented by J-M. Préaud. Six Chinese
manufacturers’ facilities were voluntarily assessed for Quality Man-
agement Systems and GMP  with the objective to identify gaps and
develop a plan, to prepare vaccines that meet WHO  prequaliﬁca-
tion. The Rotavirus vaccine development project of Wuhan Institute
of Biological Products (WIBP) served as pilot to validate new GMP
facilities for the manufacturing of oral rotavirus vaccine. In 2008
pilot facilities were built and validated, production processes devel-
oped, and validation of analytical methods was completed in 2012.
Master and working cell banks and virus seeds banks were prepared
in 2011. Mock inspection was  conducted prior to manufacturing
the ﬁrst lots at full scale, and no critical issues were identiﬁed.
Consolidation of quality systems, as recommended in the mock
inspection, is being implemented and the production of clinical
material of full liquid formulation based on stability data is in
progress.
The Vaccine Product, Price and Procurement Data and Informa-
tion Project (V3P) [1] was presented by M.  Kaddar. V3P is a three
year project, funded by the BMGF and led by WHO. The project
aims to improve the introduction and sustainable use of prior-
ity EPI vaccines through the use of vaccine product information,
price, and procurement data for evidence based decision making
on policies, addressing the vaccine implementation and procure-
ment processes. V3P’s focus is on public sector procurement for
national immunization programs of GAVI graduating and middle
income countries.
There  are multiple factors inﬂuencing vaccine prices both on
the supply and demand sides. Firstly product characteristics, such
as dose, presentation, formulation, and prequaliﬁcation status are
taken into account. Secondly, the procurement mechanism (indi-
vidual country or pooled procurement), the number of supply
intermediaries and mark-ups, the volumes and discounts, fund-
ing sources, taxes and payment terms are considered. Thirdly,
demand and supply dynamics (R&D and production costs, pro-
duction capacity, segmentation of products, trends in markets and
countries, predictability of demand, vaccine pipeline, level of com-
petition, inﬂuence of donors and partners, sources of funding,
manufacturer’s strategies, etc.) are of importance. The supply chain
structure, from manufacturer to end user may  inﬂuence costs as
well.
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The V3P project includes two phases: (I) collecting and ana-
yzing information, identifying mechanisms in consultation with
takeholders and governments3 [2], and designing a tool in consul-
ation with countries and partners; (II) testing the tool in countries,
hen implementing and evaluating its impact. Technical support
nd capacity building activities are a core component of the V3P
roject aimed to increase awareness of countries on the complex-
ty of vaccine pricing and to improve the new vaccine introduction
ecision making process.
L.  Privor-Dumm (IVAC) spoke about the additional trade-
ffs of primary container decisions in the context of vaccine
astage. She suggested that more than one container size may
e needed within countries. Five dose vials may  address issues
or some products, but not all. The international community will
eed to provide improved container level forecasts to capture
he varying needs by country to ensure production plans for
maller vial sizes match with country needs and minimize risk of
issed opportunities and/or contamination of vials if not handled
ppropriately.
. Regulatory science and access to vaccines
O. Mansoor summarized the activities of the Vaccine Presen-
ation and Packaging Advisory Group (VPPAG) which is a forum
or reaching consensus on vaccine product attributes established
y the GAVI Alliance in 2007, in response to a query from indus-
ry on guidance about the optimal number of doses per vial for
otavirus and pneumococcal conjugate vaccines to be used in
AVI-eligible countries. The two leading child killers – pneumo-
ia and diarrhea – can be largely prevented by new vaccines, and
ew technologies can help us to outreach to children in need
o deliver vaccines, in the optimal presentation. Subgroups were
ormed in 2013: one for harmonization and the second to work
n bar code, with support of GS1,4 a global organization that
upports distribution of goods. Factors driving packaging choices
nclude regulatory requirements, public sector preferences and
uidelines, and manufacturers’ choices. Over the years, an increas-
ng number of vaccines is available to children, from 6 in the
970s to over 15 in the year 2010 (depending on regional sched-
les), challenging the delivery systems, cold chain space, resources
nd immunization professionals. While the world is not on track
o achieve its United Nations proposed Millennium Development
oal (MDG) commitment to a 67% reduction in child mortality by
015, we believe that simple interventions like immunization can
hift the balance from death to life for millions of children each
ear.
D. Wood discussed existing initiatives for regulatory harmo-
ization based on use of common set of written or measurement
tandards, and also on bi-lateral or multilateral legal agreements,
uch as European Medicines Agency (EMA), Association of South-
ast Asian Nations (ASEAN), Asia Paciﬁc Economic Cooperation
APEC), East African Community, among others. On the other hand,
ome decisions can be reached without a legally-binding obligation
o do so, which he deﬁned as regulatory convergence. Platforms
o promote regulatory convergence include leveraging decisions
f others, for example through the expedited review procedure
or prequaliﬁed vaccines, joint reviews such as Article 58 pro-
ess of EMA, clinical trial applications for multi-country Trials
r the African Vaccine Regulatory Forum, AVAREF, focusing on
3 Algeria, Angola, Armenia, Azerbaijan, Bhutan, Cape Verde, Congo, Egypt, EMRO
IC  (10 countries), Indonesia, Latvia, Moldova, Mongolia, Morocco, Nepal, PAHO
ountries (Ecuador, Paraguay, Bolivia, El Salvador), Paciﬁc Islands VII (13 countries),
hilippines, Sri Lanka, South Africa, Swaziland, Thailand.
4 http://www.gs1.org/.32 (2014) 6330–6335 6333
Malaria, TB and HIV vaccine trials that have been instrumental
for consensus evaluation of trials sponsored by IFPMA members.
To inform NRAs of recently developed standards and guidelines,
WHO has conducted implementation workshops on stability eval-
uation of vaccines [3]. An additional initiative to support regulatory
harmonization and convergence is the expansion of the WHO  col-
laborating centers for standardization and regulatory evaluation
of vaccines, to include 10 centers from 10 different countries,
to support a global regulatory science agenda [4] and develop
new regulatory tools to improve access to vaccines of assured
quality.
T. Kohei, WHO  adviser to Vietnam ofﬁce, reported on the
Regional Alliance for Vaccine National Regulatory Authorities in
Western Paciﬁc. The objective of this regional alliance is to sup-
port and strengthen regulatory systems and required functions
through effective and efﬁcient coordinated mechanisms. A task-
force committee then met  in Canberra, 31 May–1 June 2012,
developed a concept paper, workplan, governance and road map,
and the alliance was  ofﬁcially launched on 14 March 2013.
Eleven countries in the region conducted self-assessment and
developed indicators of performance in eight areas of regulation
(while WHO  has deﬁned 6 areas of expertise). It was agreed that
countries with functional NRA will provide support to other coun-
tries.
J. Petricciani presented an overview of the International
Alliance for Biological Standardization (IABS) and proposed oppor-
tunities for collaborations with DCVMN. IABS is a scientiﬁc
society established in 1965, in Switzerland, to promote consen-
sus building on contemporary and emerging issues related to
medical, scientiﬁc, and technological developments in human
and veterinary biologicals, through interdisciplinary discussions,
conferences, publications and partnerships. Today it counts over
300 individual members and 12 institutional members. It has
four committees working on Human Vaccines, Veterinary Vac-
cines, Biotherapeutics, Cell & Gene therapy. Dr. Petricciani invited
DCVMN to participate in the Human Vaccines Committee and
provide perspectives on issues/topics to be considered at future
conferences.
Global activities of the UK National Institute for Biological
Standards and Control to improving vaccine quality assurance
were outlined by I. Feavers. The global vaccines landscape shows
an expanding manufacturing base that has resulted in increased
access to existing vaccines, as well as new vaccines for region-
ally important diseases, with tailored formulations (different
serotypes) and new targets (e.g. Hep E, EV71, Vi-conjugates,
etc.) contributing to health as well as economic development
for producer countries. Diseases prevented by vaccines disap-
pear, resulting in complacency, altered apparent risk/beneﬁt ratio,
and a fragile public conﬁdence. Ensuring continued supply of
safe and effective vaccines requires accurate and consistent dos-
ing (potency), consistency of manufacturing quality, and assuring
safety.
For example, Streptococcus pneumoniae is a leading cause
of bacterial pneumonia, meningitis, and sepsis in children, and
responsible for 0.7–1.0 million child deaths every year worldwide.
Over 90 serotypes of pneumococcus exist, and most disease caused
by a limited number of serotypes show regional differences in
serotype distribution. Ten- and 13-valent polysaccharide conju-
gate vaccines are widely used in Europe, the US  and Australia,
and protection is related to IgG, assessed by ELISA. Two vac-
cine manufacturers are unlikely to meet global demand. Thus
serological criteria are essential for the evaluation of new formu-
lations and new serotypes, and head-to-head comparison with
licensed product is the preferred method of efﬁcacy evaluation.
Recommendations for pneumococcal conjugated vaccines were
revised in 2009 [5] and the 1st. International Standard for Human
6 ccine 
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neumococcal Serum was established [6] and is available [7] for
trengthening the capability and the breadth of expertise in vac-
ines and to facilitate development of new vaccines and diagnostics.
V. Halkjaer-Knudsen, from Sandia National Laboratories for
iorisk management, provided an overview of vaccine GMP  pro-
uction and containment programs for eradicating, emerging,
arcinogenic, genetically modiﬁed organisms and other risks
elated to the biotechnology and vaccine industry. While GMP  aims
o protect end-users from an unsafe agent, biosafety aims to protect
he environment from harmful agents, and biosecurity, to protect
io agents from harmful uses. Vaccine production facilities should
hus identify the chain of potential infectivity, from storage of
athogens, buildings and equipment procedures, to administrative
ontrols and decontamination, ensuring that risks are controlled
hrough surveillance and quarantine, as needed. Regulatory best
ractices, codes and standards, such as ISO guidance are widely
vailable to manage risk related processes [8–15]. An international
iorisk management document (CWA 15793:2011) [16], used by
he WHO  Smallpox Lab inspection program, and the WHO  GAP III
raft [17] lay out a risk based strategic approach for mitigation
easures and controls for emerging and re-emerging infectious
iseases. New tailored facilities evolved to single-use bioreactors
idely implemented, that matured to a range of single use products
or cell cultivation, upstream and downstream processes, resulting
n cost-effective ﬂexible and scalable production suites, requiring
lmost no-cleaning validation, for easy switch of products, projects,
nd low cost start up process, increasing the complexity of reg-
latory oversight on equipment, disposable, and leachables. She
ecommended that manufacturers study the guidelines, reﬂect on
isk analysis, and decide on solutions to be discussed with health
uthorities.
A satellite symposium on new technologies for vaccine devel-
pment and supply was hosted by Merck Millipore. M.  Payne and
.Y. Lau provided an overview on cleaning and process validation
ith special emphasis on ﬁlter validation and integrity testing and
onsidered validation master plan. Implementation of single use
echnology including risk assessment approach to design and val-
dation of single use components in vaccine manufacturing were
iscussed.
. Conclusion and outlook
G.  Harshavardhan, Vice-President of DCVMN, concluded the
eeting acknowledging all speakers and participants for their
nvaluable contributions and sharing knowledge on global health
eeds, procurement and supply of vaccines, product developments,
egulatory science, manufacturing technologies and tools. Remark-
bly, in recent years innovative vaccines such as EV71, HepE,
yphoid conjugate, cell based inﬂuenza vaccines, and other vac-
ines are coming out of research by manufacturers from developing
ountries. While affordability is demanded from manufacturers at
he same time innovation and R&D is expected based on return on
nvestments, which is challenging. Further regulatory harmoniza-
ion and regulatory convergence in developing countries should be
ostered. Dr. Harshavardhan emphasized that DCVMN is fostering a
ulture of professional partnerships and continuous improvement
mong members, to supply better vaccines for healthier lives and
hus achieve our common global health goals.
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